Additional file 1: of EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Figure S1. Immunological activation profile of EnanDIM-C in comparison to the common PTO-modified CpG-ODN CpG 7909 (ProMune). In vitro stimulation of human PBMC cells at the indicated concentrations (a, b) or a final concentration of 3 μM (c) and read-out after 48 h. a, dose-dependent stimulation of cytokine/chemokine production: anti-tumor IFN-alpha (top left), anti-angiogenic IP-10 (top right), IFN-gamma (bottom left), unfavorable IL-8 (bottom right), n = 5. b, dose-dependent activation of cell surface marker CD86 on monocytes (left, n = 4), CD86 on B cells (right, n = 5). c, activation of cell surface marker CD69 on NK cells (left), CD69 on T cells (right), n = 20. Values obtained after activation with different concentrations of both TLR9 agonists were normalized to the values obtained after activation with EnanDIM-C at a final concentration of 3 μM. (PPTX 102 kb)